augmentin 875 mg/125 mg apvalkotās tabletes
glaxosmithkline (ireland) limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg
augmentin 875 mg/125 mg apvalkotās tabletes
glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg
augmentin 875 mg/125 mg apvalkotās tabletes
glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg
augmentin 500 mg/125 mg apvalkotās tabletes
glaxosmithkline single member a.e.b.e., greece - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 500 mg/125 mg
argosulfan 20 mg/g krēms
bausch + lomb ireland limited, ireland - sulfatiazola sudraba sāls - krēms - 20 mg/g
cisplatin ebewe 25 mg/50 ml koncentrāts infūziju šķīduma pagatavošanai
sandoz d.d., slovenia - cisplatīns - koncentrāts infūziju šķīduma pagatavošanai - 0,5 mg/ml
cisplatin teva 0,5 mg/ml koncentrāts infūziju šķīduma pagatavošanai
teva pharma b.v., netherlands - cisplatīns - koncentrāts infūziju šķīduma pagatavošanai - 0,5 mg/ml
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - other nervous system drugs - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.